{
    "clinical_study": {
        "@rank": "99206", 
        "brief_summary": {
            "textblock": "Primary Objective:  To estimate the rate at which radiotherapy to the primary or a\n      metastatic lesion produces an immune response in patients with metastatic carcinoma of the\n      pancreas.\n\n      Secondary Objectives: To characterize the kinetics of an immune response induced by\n      radiotherapy. To characterize the dependency of the immune response on prior exposure to\n      chemotherapy."
        }, 
        "brief_title": "A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Histological or Cytological Diagnosis of Pancreatic Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological or cytological diagnosis of pancreatic carcinoma\n\n          -  Patients \u2265 18 years of age\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0,1,or 2\n\n          -  Patients must have distant metastatic disease (stage 4)\n\n          -  Satisfactory organ and bone marrow function as defined by: Absolute neutrophil count>\n             1,000/uL, Platelets > 75,000uL Hemoglobin > 9 Bilirubin \u2264 2.0x the institutional\n             normal upper limit unless secondary to bile duct obstruction by tumor,\n\n          -  Creatinine \u2264 1.5x the institutional normal upper limit\n\n          -  Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \u2264 5x the\n             institutional normal upper limit.\n\n          -  A clinical recommendation for radiotherapy to the primary or a metastatic lesion had\n             been made.\n\n          -  Must be able to provide informed consent.\n\n        Exclusion Criteria:\n\n          -  No prior radiation to the area planned for radiotherapy\n\n          -  Active invasive cancer other than pancreatic adenocarcinoma. Non-melanoma skin\n             cancer, superficial cervical or bladder cancer and prostate cancer with PSA level <\n             1.0 are not excluded.\n\n          -  Known HIV, HCV and/or HBV positive (by patient report/medical record)\n\n          -  Patients with ongoing or active infection\n\n          -  Planned concurrent treatment with systemic high dose corticosteroids.\n\n          -  Received an anticancer treatment (systemic therapy or radiation therapy)within 21\n             days prior to enrollment.\n\n          -  Immunotherapy (e.g. monoclonal antibodies)within 21 days prior to enrollment.\n\n          -  Immunosuppressive therapies (e.g. steroids, cyclosporine) are not permitted."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01985958", 
            "org_study_id": "UPCC 14213"
        }, 
        "intervention": {
            "intervention_name": "Radiation therapy", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": "Pancrelipase"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 15, 2013", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Edgar Ben-Josef, MD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Edgar Ben-Josef, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study to Evaluate Radiotherapy-Induced Ant-Tumor Immunity in Metastatic Carcinoma of the Pancreas", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Edgar Ben-Josef, MD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Edgar Ben-Josef, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "One Year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01985958"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}